The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay

Clinical Biochemistry

Volumn 46, Issue 16-17, 2013, Pages 1705-1708

  Yang, Jingjing ^a   Sa, Mu ^a   Huang, Meng ^a   Yang, Jiajin ^a   Xiang, Zhongyuan ^a   Liu, Bo ^a   Tang, Aiguo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CA125; Electrochemiluminescence immunoassay; HE4; Reference intervals; ROMA

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; AGED; ALGORITHM; ARTICLE; CHEMOLUMINESCENCE; FEMALE; HUMAN; IMMUNOASSAY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE;

CA125; CANCER ANTIGEN 125; CHEMILUMINESCENT IMMUNOASSAY; CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY; CLIA; CMIA; ECL; ECLIA; EIA; ELECTROCHEMILUMINESCENCE; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ENZYME IMMUNOASSAY; HE4; HUMAN EPIDIDYMIS PROTEIN 4; LN; NATURAL LOGARITHM; REFERENCE INTERVALS; RIS; RISK OF OVARIAN MALIGNANCY ALGORITHM; ROMA;

AGING; ALGORITHMS; CA-125 ANTIGEN; FEMALE; HEALTH; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; PROTEINS; REFERENCE VALUES; RISK FACTORS;

EID: 84886397066     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.08.019     Document Type: Article

References (33)

1. Trudel D., Têtu B., Grégoire J., Plante M., Renaud M.C., Bachvarov D., et al. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol 2012, 127(3):511-515.
2. Clauss A., Liljia H., Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002, 368(Pt 1):233-242.
3. Li J., Dowdy S., Tipton T., Podratz K., Lu W.G., Xie X., et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009, 9(6):555-566.
4. Lin J., Qin J., Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013, 167(1):81-85.
5. Sandri M.T., Bottari F., Franchi D., Boveri S., Candiani M., Ronzoni S., et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol 2013, 128(2):233-238.
6. Yang Z., Luo Z., Zhao B., Zhang W., Zhang J., Li Z., et al. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett 2013, 6(1):28-34.
7. Saldova R., Struwe W.B., Wynne K., Elia G., Duffy M.J., Rudd P.M. Exploring the glycosylation of serum CA125. Int J Mol Sci 2013, 14(8):15636-15654.
8. Escudero J.M., Auge J.M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011, 57(11):1534-1544.
9. Anastasi E., Marchei G.G., Viggiani V., Gennarini G., Frati L., Reale M.G. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010, 31(2):113-119.
10. Huhtinen K., Suvitie P., Hiissa J., Junnila J., Huvila J., Kujari H., et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009, 100(8):1315-1319.
11. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108(2):402-408.
12. Moore R.G., McMeekin D.S., Brown A.K., DiSilvestro P., Miller M.C., Allard W.J., et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112(1):40-46.
13. Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med 2011, 49(3):521-525.
14. Jacob F., Meier M., Caduff R., Goldstein D., Pochechueva T., Hacker N., et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011, 121(3):487-491.
15. Karlsen M.A., Sandhu N., Høgdall C., Christensen I.J., Nedergaard L., Lundvall L., et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012, 127(2):379-383.
16. Molina R., Escudero J.M., Augé J.M., Filella X., Foj L., Torné A., et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol 2011, 32(6):1087-1095.
17. Kalapotharakos G., Asciutto C., Henic E., Casslén B., Borgfeldt C. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res 2012, 5(1):20.
18. Macuks R., Baidekalna I., Donina S. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumour Biol 2012, 33(5):1811-1817.
19. Yamashita S., Tokuishi K., Moroga T., Yamamoto S., Ohbo K., Miyahara S., et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression. Tumour Biol 2012, 33(6):2365-2370.
20. Angioli R., Plotti F., Capriglione S., Montera R., Damiani P., Ricciardi R., et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol 2013, 34(1):571-576.
21. Chan K.K., Chen C.A., Nam J.H., Ochiai K., Wilailak S., Choon A.T., et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol 2013, 128(2):239-244.
22. Lu L., Liu B., Zhao Z., Ma C., Luo P., Liu C., et al. Ultrasensitive electrochemical immunosensor for HE4 based on rolling circle amplification. Biosens Bioelectron 2012, 33(1):216-221.
23. Gan N., Zhou J., Xiong P., Hu F., Cao Y., Li T., et al. An ultrasensitive electrochemiluminescent immunoassay for aflatoxin M1 in milk, based on extraction by magnetic graphene and detection by antibody-labeled CdTe quantumn dots-carbon nanotubes nanocomposite. Toxins (Basel) 2013, 5(5):865-883.
24. Xiao-Yan C., Jie L., Dang J., Tao L., Xin-Ru L., Guang-Lun Z. A highly sensitive electrochemiluminescence immunoassay for detecting human embryonic human chorionic gonadotropin in spent embryo culture media during IVF-ET cycle. J Assist Reprod Genet 2013, 30(3):337-382.
25. Ceriotti F., Hinzmann R., Panteghini M. Reference intervals: the way forward. Ann Clin Biochem 2009, 46(Pt 1):8-17.
26. Li S., Lin L., Mo Z., Qin X., Lv H., Gao Y., et al. Reference values for serum ferritin in Chinese Han ethnic males: results from a Chinese male population survey. Clin Biochem 2011, 44(16):1325-1328.
27. Park Y., Kim Y., Lee E.Y., Lee J.H., Kim H.S. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer 2012, 130(5):1136-1144.
28. Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol 2012, 33(1):141-148.
29. Mokhtar N., Thevarajah M., Ma N., M I Human epididymis protein 4 reference intervals in a multiethnic Asian women population. Asian Pac J Cancer Prev 2012, 13(12):6391-6395.
30. Moore R.G., Miller M.C., Eklund E.E., Lu K.H., Bast R.C., Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012, 206(4):349.e1-349.e7.
31. Horowitz G., Altaie S., Boyd J.C., Ceriotti F., Garg U., Horn P., et al. Defining, establishing, and verifying reference intervals in the clinical laboratory. Approved guideline 2008, Clinical Laboratory and Standards Institute. 3rd ed.
32. NCCLS EP A15: user demonstration of performance for precision and accuracy; approved guideline 2001, Clinical Laboratory and Standards Institute.
33. Anastasi E., Granato T., Marchei G.G., Viggiani V., Colaprisca B., Comploj S., et al. ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010, 31(5):411-415.